Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Short Interest Update

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) was the recipient of a significant decline in short interest in the month of August. As of August 15th, there was short interest totaling 58,500 shares, adeclineof23.3% from the July 31st total of 76,300 shares. Based on an average trading volume of 44,400 shares, the days-to-cover ratio is presently 1.3 days. Currently,1.4% of the company’s shares are sold short. Currently,1.4% of the company’s shares are sold short. Based on an average trading volume of 44,400 shares, the days-to-cover ratio is presently 1.3 days.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded shares of Coeptis Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd.

Coeptis Therapeutics Trading Up 0.5%

Shares of COEP traded up $0.07 during trading hours on Tuesday, reaching $13.02. 50,254 shares of the company traded hands, compared to its average volume of 79,686. The company’s fifty day moving average price is $11.27 and its two-hundred day moving average price is $10.07. The company has a market capitalization of $62.76 million, a price-to-earnings ratio of -2.24 and a beta of -0.57. The company has a quick ratio of 0.83, a current ratio of 0.83 and a debt-to-equity ratio of 0.02. Coeptis Therapeutics has a 12 month low of $2.31 and a 12 month high of $14.70.

Coeptis Therapeutics (NASDAQ:COEP) last announced its earnings results on Thursday, August 14th. The company reported ($1.17) earnings per share for the quarter. The firm had revenue of $0.20 million for the quarter.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.